Sensei biotherapeutics reports third quarter 2024 financial results and recent business highlights

- sns-101 phase 1/2 dose expansion clinical data expected in the first half of 2025 - - organizational restructuring to focus resources on advancing the clinical development of sns-101 - - cash runway extended into the second quarter of 2026 - boston, nov. 14, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended september 30, 2024, and provided corporate updates. “the third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the phase 1 study for sns-101 across dose levels and patients with primary and acquired resistance to pd-1 inhibitors.
SNSE Ratings Summary
SNSE Quant Ranking